Orthogen said it has developed autologous biotech proteins as a viable alternative to the Cox-2 painkillers as a treatment for arthritis and cartilage degeneration in joints. The Orthokine therapy involves injections of altered proteins obtained from the patient's own blood, which minimizes the prospect of allergic reactions, according to the firm.

Full Story:

Related Summaries